S

SymBio Pharmaceuticals Ltd
TSE:4582

Watchlist Manager
SymBio Pharmaceuticals Ltd
TSE:4582
Watchlist
Price: 91 JPY 1.11%
Market Cap: 5.1B JPY

SymBio Pharmaceuticals Ltd
Free Cash Flow

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

SymBio Pharmaceuticals Ltd
Free Cash Flow Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Free Cash Flow CAGR 3Y CAGR 5Y CAGR 10Y
S
SymBio Pharmaceuticals Ltd
TSE:4582
Free Cash Flow
-ÂĄ4.8B
CAGR 3-Years
N/A
CAGR 5-Years
1%
CAGR 10-Years
-17%
Takeda Pharmaceutical Co Ltd
TSE:4502
Free Cash Flow
ÂĄ922.3B
CAGR 3-Years
5%
CAGR 5-Years
13%
CAGR 10-Years
24%
Daiichi Sankyo Co Ltd
TSE:4568
Free Cash Flow
-ÂĄ68.8B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Otsuka Holdings Co Ltd
TSE:4578
Free Cash Flow
ÂĄ269.3B
CAGR 3-Years
71%
CAGR 5-Years
21%
CAGR 10-Years
1%
Chugai Pharmaceutical Co Ltd
TSE:4519
Free Cash Flow
ÂĄ348.4B
CAGR 3-Years
5%
CAGR 5-Years
4%
CAGR 10-Years
N/A
Astellas Pharma Inc
TSE:4503
Free Cash Flow
ÂĄ334.6B
CAGR 3-Years
21%
CAGR 5-Years
18%
CAGR 10-Years
12%
No Stocks Found

SymBio Pharmaceuticals Ltd
Glance View

Market Cap
4.7B JPY
Industry
Pharmaceuticals

SymBio Pharmaceuticals Ltd. engages in the pharmaceutical business. The company is headquartered in Minato-Ku, Tokyo-To and currently employs 141 full-time employees. The company went IPO on 2011-10-20. Along with medicine specialists, contract research organizations (CROs) and other pharmaceutical companies, the Company is engaged in the design and operation of clinical tests, the manufacture and sale of new drugs specializing in three therapeutic areas: cancer, blood diseases and autoimmune diseases. The firm develops new medicines using chemical compounds proofed by preclinical tests and clinical tests. The firm manufactures and sells medicines through domestic and foreign pharmaceutical companies. The firm's pipelines include anticancer drugs, such as SyB L-0501, SyB L-1101 and SyB C-1101.

Intrinsic Value
68.9 JPY
Overvaluation 24%
Intrinsic Value
Price
S

See Also

What is SymBio Pharmaceuticals Ltd's Free Cash Flow?
Free Cash Flow
-4.8B JPY

Based on the financial report for Sep 30, 2025, SymBio Pharmaceuticals Ltd's Free Cash Flow amounts to -4.8B JPY.

What is SymBio Pharmaceuticals Ltd's Free Cash Flow growth rate?
Free Cash Flow CAGR 10Y
-17%

Over the last year, the Free Cash Flow growth was -255%.

Back to Top